RA CAPITAL MANAGEMENT, L.P. purchased $4.6M of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 531,326 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.66 ($8.57–$8.99, $4.60M total) across 3 trades over 2026-06-12 to 2026-06-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 16, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

This provides a concrete, newly disclosed ownership change (size, price range, and post-transaction holdings) that may influence short-term sentiment, but it does not introduce new operational or financial information about Artiva.

02

Market read

Traders may monitor ARTV for sentiment follow-through, but the disclosure alone is unlikely to drive a durable repricing without accompanying fundamental catalysts.

03

What to watch

The trades were executed over several days and the filing notes no 10b5-1 plan; without context on prior intent or subsequent follow-through, signal strength is uncertain.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-16; trades occurred 2026-06-12 to 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure: RA Capital Management (10% owner) bought Artiva Biotherapeutics shares in an open-market purchase.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, a 10% owner, reported an open-market purchase of 531,326 Artiva Biotherapeutics shares for ~$4.6M via SEC Form 4.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4 showing size and timing, but it lacks new company fundamentals (no trial, approval, or guidance change).

Market effects

No sector-wide implication; this is a single-company ownership transaction.

None indicated.

None indicated.

Counterpoint

Form 4 buying by a large holder can reflect portfolio rebalancing, liquidity needs, or non-informational motives rather than a change in outlook.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4; received open-market purchases reported by RA Capital Management.

  • RA Capital Management, L.P.

    Reported indirect open-market purchases totaling ~$4.6M across three trades (2026-06-12 to 2026-06-16).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.